ONKORAS-101 (ClinicalTrials.gov Identifier: NCT06343402), is a Phase 1a/1b clinical trial evaluating an investigational oral therapy in adults with advanced non-small cell lung cancer that includes a specific genetic mutation. The trial is part of a multicenter research effort.

“OSF HealthCare continues to accelerate its role in early-phase cancer research, collaborating with global biotechnology partners to bring complex clinical studies to our region.” said Dr. Jun Zhang Vice President of Oncology Reseearch at OSF HealthCare Cancer Institute. “By participating in clinical research, we are able to offer eligible patients the opportunity of early access to potentially life-saving treatments.”

The study includes evaluation of the investigational therapy both alone and in combination with another therapy, with all treatment approaches being studied for research purposes in accordance with the approved study protocol.

All clinical research conducted at OSF HealthCare undergoes rigorous review and ongoing oversight to help ensure patient safety and ethical conduct.

Patients interested in learning more about clinical research at OSF HealthCare are encouraged to speak with their care team, call (844) 673- 4467 or Email: sfmc.clinicaltrials@osfhealthcare.org